Fate Therapeutics, Inc.
FATE
$1.08
$0.087.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.74M | 1.91M | 1.63M | 1.86M | 3.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.74M | 1.91M | 1.63M | 1.86M | 3.07M |
| Cost of Revenue | 25.84M | 3.82M | 29.14M | 17.14M | 34.65M |
| Gross Profit | -24.10M | -1.91M | -27.51M | -15.28M | -31.58M |
| SG&A Expenses | 10.64M | 11.45M | 13.77M | 31.73M | 20.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.48M | 38.88M | 42.91M | 48.87M | 55.45M |
| Operating Income | -34.74M | -36.97M | -41.28M | -47.01M | -52.38M |
| Income Before Tax | -32.25M | -34.07M | -37.62M | -52.15M | -47.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.25M | -34.07M | -37.62M | -52.15M | -47.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.25M | -34.07M | -37.62M | -52.15M | -47.68M |
| EBIT | -34.74M | -36.97M | -41.28M | -47.01M | -52.38M |
| EBITDA | -31.51M | -33.69M | -37.95M | -42.20M | -47.77M |
| EPS Basic | -0.27 | -0.29 | -0.32 | -0.44 | -0.40 |
| Normalized Basic EPS | -0.17 | -0.18 | -0.20 | -0.20 | -0.25 |
| EPS Diluted | -0.27 | -0.29 | -0.32 | -0.44 | -0.40 |
| Normalized Diluted EPS | -0.17 | -0.18 | -0.20 | -0.20 | -0.25 |
| Average Basic Shares Outstanding | 119.00M | 118.53M | 118.38M | 117.79M | 117.77M |
| Average Diluted Shares Outstanding | 119.00M | 118.53M | 118.38M | 117.79M | 117.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |